アジア太平洋の細胞・遺伝子治療市場の2031年までの予測：地域別分析 - タイプ別、サービス別、規模別、サービスプロバイダー別、エンドユーザー別

アジア太平洋の細胞・遺伝子治療市場は、2023年に10億2,437万米ドルと評価され、2031年には80億1,275万米ドルに達すると予測され、2023年から2031年までのCAGRは29.3%を記録すると推定されます。

企業による戦略的取り組みがアジア太平洋の細胞・遺伝子治療市場を牽引

細胞・遺伝子治療製品の製造に携わる多くの企業は、提携、事業拡大、契約、パートナーシップ、新製品の発売、その他の戦略的開発に注力しています。これらの戦略的イニシアチブは、売上の向上、地理的範囲の拡大、大規模な顧客基盤に対応するための能力強化に役立っています。2023年9月、Agilent Technologies Inc.はシンガポールのAdvanced Cell Therapy and Research Institute（ACTRIS）と覚書を締結しました。この契約は、今後3年間にわたり細胞治療と遺伝子治療の進歩を向上させることを目的としています。2023年3月、セルボルブ・バイオはシアトル・チルドレンズ・セラピューティクスと提携し、小児がんを対象とした新しいマルチプレックスCARの開発と商業化を目指します。この提携により、両社は小児の中枢神経系（CNS）悪性腫瘍を治療するための5つのマルチプレックスCARからなるBrainChild研究プログラムに注力します。両社は、シアトル・チルドレンズ・キュア・ファクトリーの施設を活用し、新規CARの早期臨床GMP調査を実施することを目指します。2023年3月、Twist Bioscience CorporationとKriya Therapeutics, Inc.は、がん治療用途でアデノ随伴ウイルス（AAV）遺伝子治療を用いて送達される抗体に関する抗体探索契約を締結しました。また、ツイスト社の抗体ライブラリーとクリヤ社独自のベクターエンジニアリングプラットフォームを組み合わせ、クリヤ社の遺伝子治療技術で送達される特定の標的に対する新規抗体の創出を目指します。2023年1月、富士フイルムはAtara Biotherapeutics, Inc.から細胞治療製造施設を買収することに合意しました。この施設は、同種T細胞免疫療法やCAR T免疫療法などの臨床および商業用細胞療法を製造する柔軟性を備えた拡張施設となります。共同研究や提携を通じて市場競争力を維持するために新規事業を開始することは、細胞・遺伝子治療製造サービスの新たなプラットフォームの開発を加速させるのに役立ちます。このように、主要企業によるこうした戦略的イニシアチブは、予測期間中にアジア太平洋の細胞・遺伝子治療市場に大きな成長機会をもたらすと予想されます。

アジア太平洋の細胞・遺伝子治療市場概要

中国は遺伝子・細胞治療の分野で進歩を遂げています。同国は患者数が多く、これらの治療を開発する企業にとって魅力的な市場となっています。中国では複数の企業ががんや遺伝性疾患などの疾患に対する革新的な治療に取り組んでおり、遺伝子治療の研究開発にも多額の投資を行っています。中国は2003年に遺伝子治療を承認した最初の国です。それ以来、細胞治療と遺伝子治療の開発は世界中で急速に進展し、その治療可能性は急上昇しています。中華人民共和国政府は、細胞治療と遺伝子治療の規範的発展を促進するために、いくつかの規制改革を行ってきました。2021年にネイチャー誌に発表された研究によると、中国は世界の細胞治療試験の50％以上を実施しています。中国では、血液学、腫瘍学、固形腫瘍を中心に400近くのCAR-T試験が進行中です。中国では、2021年にFosun Kite社のYescartaとJW Therapeutics社のRelma-celが国家医薬品監督管理局（NMPA）から承認され、細胞治療は新たな時代を迎えようとしています。2023年10月には、CARsgenとIASO Biotherapeutics/Innoventが、CAR-TのB細胞成熟抗原を標的とした新薬承認でNMPAから承認されました。これらの治療法は間もなく承認され、商業化される見込みです。

アジア太平洋の細胞・遺伝子治療市場の収益と2031年までの予測（金額）

アジア太平洋の細胞・遺伝子治療市場のセグメンテーション

アジア太平洋の細胞・遺伝子治療市場は、タイプ、サービス、規模、エンドユーザー、国に分類されます。

タイプ別に見ると、アジア太平洋の細胞・遺伝子治療市場は細胞治療と遺伝子治療に二分されます。2023年には、細胞療法セグメントがより大きな市場シェアを占めています。さらに、細胞療法セグメントは同種、自家、ウイルスベクターに細分化されます。さらに、遺伝子治療セグメントは非ウイルスベクターとウイルスベクターに分けられます。

サービスの面では、アジア太平洋の細胞・遺伝子治療市場はプロセス開拓、cGMP製造、規制サービス、バイオアッセイサービスに分類されます。2023年にはプロセス開発分野が最大の市場シェアを占めています。

規模別では、アジア太平洋の細胞・遺伝子治療市場はプレコマーシャル/研究開発製造と商業規模製造に二分されます。2023年には、プレコマーシャル/R&D製造セグメントがより大きな市場シェアを占めました。

エンドユーザー別に見ると、アジア太平洋の細胞・遺伝子治療市場は、契約研究機関、製薬・バイオ製薬企業、学術・研究機関に区分されます。製薬・バイオ製薬企業セグメントが2023年に最大の市場シェアを占めました。

国別では、アジア太平洋の細胞・遺伝子治療市場は中国、日本、インド、オーストラリア、韓国、その他アジア太平洋地域に区分されます。2023年のアジア太平洋の細胞・遺伝子治療市場シェアは中国が独占しました。

Catalent Inc、Charles River Laboratories International Inc、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、Lotte Corp、Merck KGaA、Takara Bio Inc、Thermo Fisher Scientific Inc.、WuXi AppTec Co Ltdは、アジア太平洋の細胞・遺伝子治療市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

• 主要な洞察

第3章 調査手法

• 2次調査
• 1次調査
  • 仮説の策定
  • マクロ経済要因分析
  • ファンデーション数値の開発
  • データの三角測量
  • 国レベルのデータ

第4章 アジア太平洋の細胞・遺伝子治療市場情勢

• PEST分析

第5章 アジア太平洋の細胞・遺伝子治療市場：主要市場力学

• 細胞・遺伝子治療市場：主要市場力学
• 市場促進要因
  • 細胞・遺伝子治療の承認件数の増加
  • 細胞・遺伝子治療製造のアウトソーシングの急速な普及
• 市場抑制要因
  • 細胞・遺伝子治療製造の高コスト
• 市場機会
  • 企業による戦略的取り組み
• 今後の動向
  • 細胞・遺伝子治療製造サービスの自動化
• 促進要因と抑制要因の影響

第6章 細胞・遺伝子治療市場：アジア太平洋市場分析

• アジア太平洋の細胞・遺伝子治療市場概要
• アジア太平洋の細胞・遺伝子治療市場収益、2021～2031年
• 細胞・遺伝子治療市場の予測分析

第7章 アジア太平洋の細胞・遺伝子治療市場分析：タイプ別

• 細胞療法
• 遺伝子治療

第8章 アジア太平洋の細胞・遺伝子治療市場分析：サービス別

• プロセス開発
• cGMP製造
• 薬事サービス
• バイオアッセイサービス

第9章 アジア太平洋の細胞・遺伝子治療市場分析：規模別

• プレコマーシャル/R&D製造
• 商業スケール製造

第10章 アジア太平洋の細胞・遺伝子治療市場分析：サービスプロバイダー別

• CDMO
• CMO

第11章 アジア太平洋の細胞・遺伝子治療市場分析：エンドユーザー別

• 契約研究機関
• 製薬・バイオ製薬企業
• 学術・研究機関

第12章 アジア太平洋の細胞・遺伝子治療市場：国別分析

• アジア太平洋地域
• 中国
• 日本
• インド
• オーストラリア
• 韓国
• その他アジア太平洋地域

第13章 業界情勢

• 細胞・遺伝子治療市場における成長戦略
• 有機的成長戦略
• 無機的成長戦略

第14章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Charles River Laboratories International Inc
• Lonza Group AG
• WuXi AppTec Co Ltd
• Takara Bio Inc
• FUJIFILM Holdings Corp
• F. Hoffmann-La Roche Ltd
• Catalent Inc
• Lotte Corp

第15章 付録

List Of Tables

• Table 1. Cell and Gene Therapy Market Segmentation
• Table 2. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Table 3. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Type
• Table 4. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Cell Therapy
• Table 5. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Gene Therapy
• Table 6. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Services
• Table 7. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Scale
• Table 8. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Service Providers
• Table 9. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by End User
• Table 10. Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Country
• Table 11. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 12. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
• Table 13. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
• Table 14. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
• Table 15. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
• Table 16. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
• Table 17. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
• Table 18. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 19. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
• Table 20. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
• Table 21. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
• Table 22. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
• Table 23. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
• Table 24. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
• Table 25. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 26. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
• Table 27. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
• Table 28. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
• Table 29. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
• Table 30. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
• Table 31. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
• Table 32. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 33. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
• Table 34. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
• Table 35. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
• Table 36. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
• Table 37. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
• Table 38. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
• Table 39. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 40. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
• Table 41. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
• Table 42. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
• Table 43. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
• Table 44. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
• Table 45. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
• Table 46. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 47. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
• Table 48. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
• Table 49. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
• Table 50. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
• Table 51. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
• Table 52. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
• Table 53. Recent Organic Growth Strategies in Cell and Gene Therapy Market
• Table 54. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Market
• Table 55. Glossary of Terms

List Of Figures

• Figure 1. Cell and Gene Therapy Market Segmentation, by Country
• Figure 2. PEST Analysis
• Figure 3. Impact Analysis of Drivers and Restraints
• Figure 4. Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
• Figure 5. Cell and Gene Therapy Market Share (%) - by Type (2023 and 2031)
• Figure 6. Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 7. Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 8. Cell and Gene Therapy Market Share (%) - by Services (2023 and 2031)
• Figure 9. Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 10. cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 11. Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 12. Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 13. Cell and Gene Therapy Market Share (%) - by Scale (2023 and 2031)
• Figure 14. Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 15. Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 16. Cell and Gene Therapy Market Share (%) - by Service Providers (2023 and 2031)
• Figure 17. CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 18. CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 19. Cell and Gene Therapy Market Share (%) - by End User (2023 and 2031)
• Figure 20. Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 21. Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 22. Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 23. Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 24. Asia Pacific Cell and Gene Therapy Market Breakdown, by Key Countries, 2023 and 2031 (%)
• Figure 25. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 26. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 27. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 28. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 29. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 30. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
• Figure 31. Growth Strategies in Cell and Gene Therapy Market

The Asia Pacific cell and gene therapy market was valued at US$ 1,024.37 million in 2023 and is projected to reach US$ 8,012.75 million by 2031; it is estimated to record a CAGR of 29.3% from 2023 to 2031.

Strategic Initiatives by Companies Drive Asia Pacific Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are; In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years. In March 2023, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2023, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2023, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies. The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the Asia Pacific cell and gene therapy market during the forecast period.

Asia Pacific Cell and Gene Therapy Market Overview

China is making progress in gene and cell therapy. The country has a large patient population making it an attractive market for companies developing these treatments. Several companies are working on innovative therapies for diseases such as cancer and genetic disorders in China, and the country has invested heavily in gene therapy research and development. China was the first country to approve gene therapy in 2003; since then, cell and gene therapy developments have advanced rapidly worldwide, and their therapeutic potential has soared. The government of the People's Republic of China has conducted several regulatory reforms to promote the normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials worldwide. China has nearly 400 ongoing CAR-T trials centered on hematology, oncology, and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). In October 2023, CARsgen and IASO Biotherapeutics/Innovent were approved by the NMPA for new drug approvals targeting B-cell maturation antigens in CAR-T. These therapies are expected to be approved and commercialized soon.

Asia Pacific Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Cell and Gene Therapy Market Segmentation

The Asia Pacific cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Asia Pacific cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Asia Pacific cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Asia Pacific cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Asia Pacific cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Asia Pacific cell and gene therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific Cell and Gene Therapy Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis

5. Asia Pacific Cell and Gene Therapy Market - Key Market Dynamics

• 5.1 Cell and Gene Therapy Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
  • 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
• 5.3 Market Restraints
  • 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
• 5.4 Market Opportunities
  • 5.4.1 Strategic Initiatives by Companies
• 5.5 Future Trends
  • 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
• 5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -Asia Pacific Market Analysis

• 6.1 Asia Pacific Cell and Gene Therapy Market Overview
• 6.2 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
• 6.3 Cell and Gene Therapy Market Forecast Analysis

7. Asia Pacific Cell and Gene Therapy Market Analysis - by Type

• 7.1 Cell Therapy
  • 7.1.1 Overview
  • 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 7.2 Gene Therapy
  • 7.2.1 Overview
  • 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Market Analysis - by Services

• 8.1 Process Development
  • 8.1.1 Overview
  • 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 8.2 cGMP Manufacturing
  • 8.2.1 Overview
  • 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Regulatory Services
  • 8.3.1 Overview
  • 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 8.4 Bioassay Services
  • 8.4.1 Overview
  • 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Market Analysis - by Scale

• 9.1 Pre-Commercial/R&D Manufacturing
  • 9.1.1 Overview
  • 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 9.2 Commercial Scale Manufacturing
  • 9.2.1 Overview
  • 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Market Analysis - by Service Providers

• 10.1 CDMOs
  • 10.1.1 Overview
  • 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 10.2 CMOs
  • 10.2.1 Overview
  • 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Market Analysis - by End User

• 11.1 Contract Research Organizations
  • 11.1.1 Overview
  • 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 11.2 Pharmaceutical and Biopharmaceutical Companies
  • 11.2.1 Overview
  • 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
• 11.3 Academic and Research Institutes
  • 11.3.1 Overview
  • 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Asia Pacific Cell and Gene Therapy Market - Country Analysis

• 12.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 12.1.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
    • 12.1.1.1 Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
    • 12.1.1.2 China: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
      • 12.1.1.2.1 China: Cell and Gene Therapy Market Breakdown, by Type
        • 12.1.1.2.1.1 China: Cell and Gene Therapy Market Breakdown, by Cell Therapy
        • 12.1.1.2.1.2 China: Cell and Gene Therapy Market Breakdown, by Gene Therapy
      • 12.1.1.2.2 China: Cell and Gene Therapy Market Breakdown, by Services
      • 12.1.1.2.3 China: Cell and Gene Therapy Market Breakdown, by Scale
      • 12.1.1.2.4 China: Cell and Gene Therapy Market Breakdown, by Service Providers
      • 12.1.1.2.5 China: Cell and Gene Therapy Market Breakdown, by End User
    • 12.1.1.3 Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
      • 12.1.1.3.1 Japan: Cell and Gene Therapy Market Breakdown, by Type
        • 12.1.1.3.1.1 Japan: Cell and Gene Therapy Market Breakdown, by Cell Therapy
        • 12.1.1.3.1.2 Japan: Cell and Gene Therapy Market Breakdown, by Gene Therapy
      • 12.1.1.3.2 Japan: Cell and Gene Therapy Market Breakdown, by Services
      • 12.1.1.3.3 Japan: Cell and Gene Therapy Market Breakdown, by Scale
      • 12.1.1.3.4 Japan: Cell and Gene Therapy Market Breakdown, by Service Providers
      • 12.1.1.3.5 Japan: Cell and Gene Therapy Market Breakdown, by End User
    • 12.1.1.4 India: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
      • 12.1.1.4.1 India: Cell and Gene Therapy Market Breakdown, by Type
        • 12.1.1.4.1.1 India: Cell and Gene Therapy Market Breakdown, by Cell Therapy
        • 12.1.1.4.1.2 India: Cell and Gene Therapy Market Breakdown, by Gene Therapy
      • 12.1.1.4.2 India: Cell and Gene Therapy Market Breakdown, by Services
      • 12.1.1.4.3 India: Cell and Gene Therapy Market Breakdown, by Scale
      • 12.1.1.4.4 India: Cell and Gene Therapy Market Breakdown, by Service Providers
      • 12.1.1.4.5 India: Cell and Gene Therapy Market Breakdown, by End User
    • 12.1.1.5 Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
      • 12.1.1.5.1 Australia: Cell and Gene Therapy Market Breakdown, by Type
        • 12.1.1.5.1.1 Australia: Cell and Gene Therapy Market Breakdown, by Cell Therapy
        • 12.1.1.5.1.2 Australia: Cell and Gene Therapy Market Breakdown, by Gene Therapy
      • 12.1.1.5.2 Australia: Cell and Gene Therapy Market Breakdown, by Services
      • 12.1.1.5.3 Australia: Cell and Gene Therapy Market Breakdown, by Scale
      • 12.1.1.5.4 Australia: Cell and Gene Therapy Market Breakdown, by Service Providers
      • 12.1.1.5.5 Australia: Cell and Gene Therapy Market Breakdown, by End User
    • 12.1.1.6 South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
      • 12.1.1.6.1 South Korea: Cell and Gene Therapy Market Breakdown, by Type
        • 12.1.1.6.1.1 South Korea: Cell and Gene Therapy Market Breakdown, by Cell Therapy
        • 12.1.1.6.1.2 South Korea: Cell and Gene Therapy Market Breakdown, by Gene Therapy
      • 12.1.1.6.2 South Korea: Cell and Gene Therapy Market Breakdown, by Services
      • 12.1.1.6.3 South Korea: Cell and Gene Therapy Market Breakdown, by Scale
      • 12.1.1.6.4 South Korea: Cell and Gene Therapy Market Breakdown, by Service Providers
      • 12.1.1.6.5 South Korea: Cell and Gene Therapy Market Breakdown, by End User
    • 12.1.1.7 Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
      • 12.1.1.7.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Type
        • 12.1.1.7.1.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Cell Therapy
        • 12.1.1.7.1.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Gene Therapy
      • 12.1.1.7.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Services
      • 12.1.1.7.3 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Scale
      • 12.1.1.7.4 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Service Providers
      • 12.1.1.7.5 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

• 13.1 Overview
• 13.2 Growth Strategies in Cell and Gene Therapy Market
• 13.3 Organic Growth Strategies
  • 13.3.1 Overview
• 13.4 Inorganic Growth Strategies
  • 13.4.1 Overview

14. Company Profiles

• 14.1 Thermo Fisher Scientific Inc.
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
• 14.2 Merck KGaA
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
• 14.3 Charles River Laboratories International Inc
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
• 14.4 Lonza Group AG
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
• 14.5 WuXi AppTec Co Ltd
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
• 14.6 Takara Bio Inc
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
• 14.7 FUJIFILM Holdings Corp
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
• 14.8 F. Hoffmann-La Roche Ltd
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
• 14.9 Catalent Inc
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
• 14.10 Lotte Corp
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments

15. Appendix

• 15.1 About The Insight Partners
• 15.2 Glossary of Terms